{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:34:23Z","timestamp":1760243663804,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multiple myeloma (MM) is a hematologic cancer defined by an abnormal development of clonal plasma cells in the bone marrow, releasing vast quantities of immunoglobulins and different proteins. In the majority of patients, MM remains incurable despite decades of medical improvement and a number of treatment breakthroughs. Frontline standard-of-care has little long-term success, with the majority of patients eventually relapsing, although the overall progression-free survival (PFS) has improved significantly in the last ten years. Patients who are eligible for a transplant have the highest PFS rate at 5 years, depending on medication response and other various factors that are yet to be discovered. Therefore, the current study aimed to evaluate the response to VCD (bortezomib, cyclophosphamide, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) used as pretransplant regimens, as well as to compare responses between thalidomide and lenalidomide used as maintenance therapy posttransplant. This retrospective study was performed on a group of 105 hospitalized patients in the Hematology Department of the Timisoara Municipal Emergency Clinical Hospital between January 2016 and December 2021. Data was collected from the paper records of patients with MM who were under-followed. The treatment regimens used as induction therapy were either VCD or VTD if cyclophosphamide was contraindicated. Of the 105 patients, 27 became eligible for bone marrow transplantation. Furthermore, they received maintenance therapy which was based on either lenalidomide with dexamethasone or thalidomide with dexamethasone. Of the 62 patients treated with VTD, 17.7% were in complete remission before stem cell transplantation. Of the 43 patients treated with VCD, 37.2% were in complete remission. The 5-year mean progression-free survival (PFS) in the entire cohort was better in the group treated with the VTD regimen (31.6 vs. 27.2 months). However, in the 27 patients undergoing maintenance after ASCT, the PFS with thalidomide was 35.5 months (95% CI = 27\u201342), while the PFS rate in those receiving maintenance treatment with lenalidomide was 46.1 months (95% CI = 20\u201373). VCD proved to be superior to VTD in inducing complete pretransplant responses. Regarding maintenance therapy, patients from the lenalidomide group had superior responses compared with those under thalidomide.<\/jats:p>","DOI":"10.3390\/curroncol29110670","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T02:34:52Z","timestamp":1667961292000},"page":"8501-8512","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients"],"prefix":"10.3390","volume":"29","author":[{"given":"Cristina","family":"Potre","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Discipline of Hematology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ema","family":"Borsi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Discipline of Hematology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-1344","authenticated-orcid":false,"given":"Ovidiu","family":"Potre","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Discipline of Hematology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5358-882X","authenticated-orcid":false,"given":"Miruna","family":"Samfireag","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Discipline of Clinical Practical Skills, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5944-3522","authenticated-orcid":false,"given":"Dan","family":"Costachescu","sequence":"additional","affiliation":[{"name":"Discipline of Radiology and Medical Imaging, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Cerbu","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-4315","authenticated-orcid":false,"given":"Felix","family":"Bratosin","sequence":"additional","affiliation":[{"name":"Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1355-3790","authenticated-orcid":false,"given":"Cristina","family":"Secosan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica Anamaria","family":"Negrean","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dima, D., Jiang, D., Singh, D.J., Hasipek, M., Shah, H.S., Ullah, F., Khouri, J., Maciejewski, J.P., and Jha, B.K. (2022). Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers, 14.","DOI":"10.3390\/cancers14174082"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Boeriu, E., Borda, A., Vulcanescu, D.D., Sarbu, V., Arghirescu, S.T., Ciorica, O., Bratosin, F., Marincu, I., and Horhat, F.G. (2022). Diagnosis and Management of Febrile Neutropenia in Pediatric Oncology Patients\u2014A Systematic Review. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081800"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: A review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease","volume":"19","author":"Agarwal","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pinto, V., Bergantim, R., Caires, H.R., Seca, H., Guimar\u00e3es, J.E., and Vasconcelos, M.H. (2020). Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers, 12.","DOI":"10.3390\/cancers12020407"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bachmann, F., Schreder, M., Engelhardt, M., Langer, C., Wolleschak, D., M\u00fcgge, L.O., D\u00fcrk, H., Sch\u00e4fer-Eckart, K., Blau, I.W., and Gramatzki, M. (2021). Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. Cancers, 13.","DOI":"10.3390\/cancers13061322"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2018024794","article-title":"Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma","volume":"2","author":"Aljama","year":"2018","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1178224219868235","DOI":"10.1177\/1178224219868235","article-title":"Multiple myeloma: An overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat. Care Soc. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cll.2017.08.001","article-title":"Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry","volume":"37","author":"Soh","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nunnelee, J., Cottini, F., Zhao, Q., Faisal, M.S., Elder, P., Rosko, A., Bumma, N., Khan, A., Devarakonda, S., and Benson, D.M. (2022). Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. Cancers, 14.","DOI":"10.3390\/cancers14092277"},{"key":"ref_11","first-page":"227","article-title":"Expression and significance of Ki-67 in lung cancer","volume":"59","author":"Folescu","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Marincu, I., Bratosin, F., Curescu, M., Suciu, O., Turaiche, M., Cerbu, B., and Vidican, I. (2021). Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania. Medicina, 57.","DOI":"10.3390\/medicina57090986"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41408-018-0163-7","article-title":"Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: Comparative effectiveness analysis of modern induction regimens on outcome","volume":"8","author":"Paquin","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41408-019-0176-x","article-title":"Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: Impact of an MGUS-like signature","volume":"9","author":"Mateos","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/SLA.0000000000003042","article-title":"A Comparative Analysis of Survival and Funding Discrepancies in Cancers With High Mortality","volume":"271","author":"Hall","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Jianu, C., Gole\u021b, I., Stoin, D., Cocan, I., Bujanc\u0103, G., Mi\u0219c\u0103, C., Mioc, M., Mioc, A., \u0218oica, C., and Lukinich-Gruia, A.T. (2021). Chemical Profile of Ruta graveolens, Evaluation of the Antioxidant and Antibacterial Potential of Its Essential Oil, and Molecular Docking Simulations. Appl. Sci., 11.","DOI":"10.3390\/app112411753"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ioan Faur, C., Abu-Awwad, A., Pop, D.L., Zamfir, C.L., Gurgus, D., Hoinoiu, T., Motoc, A., Haivas, C., Grigora\u0219, M.L., and Folescu, R. (2020). Liquid Nitrogen Efficiency in Treatment of Giant Cell Tumor of Bone and Prevention of Recurrence. Appl. Sci., 10.","DOI":"10.3390\/app10186310"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Poczta, A., Rogalska, A., and Marczak, A. (2021). Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies\u2014Current Research and Clinical Approaches. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091841"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current Treatment Strategies for Multiple Myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino, M., Bertamini, L., Oliva, S., Boccadoro, M., and Gay, F. (2019). Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. Cancers, 11.","DOI":"10.3390\/cancers11122015"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jeryczynski, G., Bolomsky, A., Agis, H., and Krauth, M.-T. (2021). Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. Cancers, 13.","DOI":"10.3390\/cancers13235886"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4812637","DOI":"10.1155\/2017\/4812637","article-title":"The Evolution of Prognostic Factors in Multiple Myeloma","volume":"2017","author":"Hanbali","year":"2017","journal-title":"Adv. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gengenbach, L., Graziani, G., Reinhardt, H., R\u00f6sner, A., Braun, M., M\u00f6ller, M.D., Greil, C., W\u00e4sch, R., and Engelhardt, M. (2021). Choosing the Right Therapy for Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. Cancers, 13.","DOI":"10.3390\/cancers13174320"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3904\/kjim.2016.054","article-title":"Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma","volume":"32","author":"Kim","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_29","unstructured":"World Health Organization (2004). ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, World Health Organization. [2nd ed.]. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/42980."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2009.61","article-title":"Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant","volume":"23","author":"Hari","year":"2009","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/s41409-019-0629-7","article-title":"Benefits of additional cycles of bortezomib\/thalidomide\/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma","volume":"54","author":"Lee","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1200\/EDBK_238527","article-title":"Induction Therapy for Newly Diagnosed Multiple Myeloma","volume":"39","author":"Paul","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8540","DOI":"10.1200\/JCO.2020.38.15_suppl.8540","article-title":"Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials","volume":"38","author":"Giri","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cazaubiel, T., Mulas, O., Montes, L., Schavgoulidze, A., Avet-Loiseau, H., Corre, J., and Perrot, A. (2020). Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12123497"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multipelt myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yarlagadda, L., Gundarlapalli, S., Parikh, R., Landes, R.D., Kottarathara, M., Ogunsesan, Y., Hoque, S., Mitma, A.A., Bailey, C., and Hill, K.M. (2021). Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13164019"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41375-019-0383-2","article-title":"Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?","volume":"33","author":"Gale","year":"2019","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/ejh.13497","article-title":"Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment","volume":"105","author":"Ramsden","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and Years of Life Lost in Different Age Cohorts of Patients with Multiple Myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/670\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:47Z","timestamp":1760145167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["curroncol29110670"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29110670","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,11,8]]}}}